FDA evidence review of CJC-1295-related compounded substances
FDA states available clinical data are limited and has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction.
What this study tells us
This is a regulator evidence review, not a participant treatment trial. It is useful for showing what human exposure or safety evidence the regulator could — or could not — identify.
Published healthy-adult clinical studies plus other exposure reports
n=Not applicable
FDA states available clinical data are limited and has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction.
FDA notes ambiguity about the exact CJC-1295 substance/salt used in some literature; results cannot be transferred across DAC/no-DAC marketplace labels.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
FDA states available clinical data are limited and has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction.